How to stop disproportionation of a hydrochloride salt of a very weakly basic compound in a non-clinical suspension formulation

Int J Pharm. 2021 Sep 5:606:120875. doi: 10.1016/j.ijpharm.2021.120875. Epub 2021 Jul 15.

Abstract

Our objectives were to stabilize a non-clinical suspension for use in toxicological studies and to develop methods to investigate the stability of the formulation in terms of salt disproportionation. The compound under research was a hydrochloride salt of a practically insoluble discovery compound ODM-203. The first of the three formulation approaches was a suspension prepared and stored at room temperature. The second formulation was stabilized by pH adjustment. In the third approach cooling was used to prevent salt disproportionation. 5 mg/mL aqueous suspension consisting of 20 mg/mL PVP/VA and 5 mg/mL Tween 80 was prepared for each of the approaches. The polymer was used as precipitation inhibitor to provide prolonged supersaturation while Tween 80 was used to enhance dissolution and homogeneity of the suspension. The consequences of salt disproportionation were studied by a small-scale in vitro dissolution method and by an in vivo pharmacokinetic study in rats. Our results show that disproportionation was successfully suppressed by applying cooling of the suspension in an ice bath at 2-8 °C. This procedure enabled us to proceed to the toxicological studies in rats. The in vivo study results obtained for the practically insoluble compound showed adequate exposures with acceptable variation at each dose level.

Keywords: Biorelevant dissolution; In situ fiber optics; Salt disproportionation; Suspension stability; XRPD.

MeSH terms

  • Animals
  • Chemistry, Pharmaceutical*
  • Excipients*
  • Hydrochloric Acid
  • Rats
  • Solubility
  • Suspensions

Substances

  • Excipients
  • Suspensions
  • Hydrochloric Acid